Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma

Cancer
Constantine S TamJohn Seymour

Abstract

The combination of fludarabine, cyclophosphamide, and rituximab (FC-R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity. Between December 2000 and June 2005, 77 patients completed therapy after a median of 4 cycles of FC-R (fludarabine at a dose of 25 mg/m2 intravenously [i.v.] on Days 1-3, cyclophosphamide at a dose of 250 mg/m2 i.v. on Days 1-3, and rituximab at a dose of 375 mg/m2 on Day 1). The median age of the patients was 59 years, 65% were male; 31% had previously untreated disease; and 44% had chronic lymphocytic leukemia (CLL), 29% had follicular lymphoma, and 27% other indolent lymphoid malignancies. In addition to standard disease response criteria, patients underwent evaluation using flow cytometric and/or molecular studies. Objective responses (OR) and complete responses (CR) were observed in 83% and 42%, respectively, of evaluable patients (n=76), respectively. For patients with CLL, the respective OR and CR rates were 100% and 67% as firstline therapy, and 95% and 14% as salvage therapy. For patients with follicular lymphoma, the respective OR and CR rates were 100% and 86% as firstline therapy, and 87% and 67% as salvage therapy. Responders who had no detecta...Continue Reading

References

May 1, 1993·European Journal of Haematology·P W WijermansH L Haak
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinF Cabanillas
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Oct 3, 1998·Annals of Internal Medicine·E J AnaissieM J Keating
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC A White
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F SeymourR M Fox
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William WierdaMichael Keating
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian

❮ Previous
Next ❯

Citations

Jan 1, 2008·Current Hematologic Malignancy Reports·Carmen Diana SchweighoferClemens-Martin Wendtner
Aug 21, 2007·Current Oncology Reports·Deepa Sampath, William Plunkett
Jul 7, 2010·Nature Reviews. Clinical Oncology·Constantine S Tam, Michael J Keating
May 28, 2010·Molecular Cancer·Manuela FerracinAntonio Cuneo
Apr 26, 2014·Immunotherapy·Laetitia Souchet-CömpainStéphanie Nguyen
Jan 1, 2010·International Journal of Proteomics·Carlos CassanoRichard I Christopherson
Sep 13, 2012·Leukemia & Lymphoma·Constantine S Tam, Michael J Keating
Sep 13, 2014·Leukemia & Lymphoma·Nimish ShahSimon Rule
Apr 7, 2010·Leukemia & Lymphoma·Myron S Czuczman, Stephanie A Gregory
Mar 21, 2009·FEBS Letters·Nicole BarberRichard I Christopherson
Sep 29, 2015·Expert Review of Anticancer Therapy·Sara SteffanoniAlden Moccia
Jun 21, 2013·Expert Review of Hematology·Laetitia Souchet-CompainVéronique Leblond
Apr 7, 2010·La Revue de médecine interne·S PoulainX Leleu
Apr 14, 2009·Clinical Lymphoma & Myeloma·Alessandra TedeschiEnrica Morra
Oct 29, 2008·Hematology/oncology Clinics of North America·Stefan Peinert, John F Seymour
Jun 17, 2008·Cancer Letters·Xavier LeleuIrene M Ghobrial
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Constantine S Tam, Michael J Keating
Aug 4, 2007·British Journal of Haematology·Rafael Fonseca, Suzanne Hayman
Dec 18, 2008·European Journal of Haematology·Xavier LeleuIrene M Ghobrial
Sep 25, 2012·American Journal of Hematology·Arnold Freedman
Aug 19, 2011·American Journal of Hematology·Arnold Freedman
Mar 3, 2010·American Journal of Hematology·Rebecca L OlinCharalambos Andreadis
Mar 28, 2013·Clinical Lymphoma, Myeloma & Leukemia·Laetitia Souchet-CompainVéronique Leblond
Mar 16, 2013·Clinical Lymphoma, Myeloma & Leukemia·Alessandra TedeschiEnrica Morra
Apr 6, 2016·The Korean Journal of Internal Medicine·Young-Woo Jeon, Seok-Goo Cho
Mar 31, 2015·Blood Cancer Journal·A Oza, S V Rajkumar
May 3, 2016·American Journal of Hematology·Laetitia SouchetUNKNOWN FILO (French Innovative Leukemia Organization)

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.